Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12198493 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Vadlamudi RK, et al. (2002) Filamin is essential in actin cytoskeletal assembly mediated by p21-activated kinase 1. Nat Cell Biol 4, 681-90 12198493
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S2152-p - FLNA (human)
Orthologous residues
FLNA (human): S2152‑p, FLNA iso2 (human): S2144‑p, FLNA (mouse): S2152‑p, FLNA (rat): S2144‑p
Characterization
 Methods used to characterize site in vivo [32P] bio-synthetic labeling, mutation of modification site
 Disease tissue studied:  breast cancer, melanoma skin cancer
 Relevant cell lines - cell types - tissues:  A7 (melanocyte), M2 (melanocyte), MCF-7 (breast cell)
 Cellular systems studied:  cell lines
 Species studied:  human
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK1 (human)
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE PAK1 (human) transfection of constitutively active enzyme, co-immunoprecipitation, pharmacological activator of upstream enzyme, inhibition of upstream enzyme, transfection of dominant-negative enzyme, microscopy-colocalization
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
heregulin increase
peptide inhibitor heregulin inhibit treatment-induced increase PAK1 auto-inhibitory domain
Downstream Regulation
 Effect of modification (process):  cytoskeletal reorganization

S2292-p - FLNA (human)
Orthologous residues
FLNA (human): S2292‑p, FLNA iso2 (human): S2284‑p, FLNA (mouse): S2292‑p, FLNA (rat): S2284‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK1 (human)

S2370-p - FLNA (human)
Orthologous residues
FLNA (human): S2370‑p, FLNA iso2 (human): S2362‑p, FLNA (mouse): S2370‑p, FLNA (rat): S2362‑p
Characterization
 Enzymes shown to modify site in vitro
Type Enzyme
KINASE PAK1 (human)


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.